Tune in to Safe Healthcare: Unsafe Injection Stories from the Field

Abbigail Tumpey, MPH, CHES

Associate Director for Communications Science,
Division of Healthcare Quality Promotion
Centers for Disease Control and Prevention

July 26th, 2016
Continuing Education Information

ACCREDITATION STATEMENTS:

CME: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this enduring activity for a maximum of (1) AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity provides (1) contact hours.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer (0.1) CEU's for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES) and/or Master Certified Health Education Specialists (MCHES) to receive up to (1) total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. CDC provider number 98614.
Continuing Education Information Continued

CPE: The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This program is a designated event for pharmacists to receive (1) Contact Hours in pharmacy education. The Universal Activity Number is 0387-0000-16-147-L05-P.

Category: This activity has been designated as Knowledge-Based.

Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.

For Certified Public Health Professionals (CPH)

The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer (1) CPH recertification credits for this program.

CDC is an approved provider of CPH Recertification Credits by the National Board of Public Health Examiners. Effective October 1, 2013, the National Board of Public Health Examiners (NBPHE) accepts continuing education units (CEU) for CPH recertification credits from CDC. Please select CEU as your choice for continuing education when registering for a course on TCEOnline. Learners seeking CPH should use the guidelines provided by the NBPHE for calculating recertification credits. For assistance please contact NBPHE at http://www.NBPHE.org.
Continuing Education Disclosure Statement

DISCLOSURE: In compliance with continuing education requirements, all presenters must disclose any financial or other associations with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters as well as any use of unlabeled product(s) or product(s) under investigational use.

CDC, our planners, presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept commercial support for this continuing education activity.
Featured Speakers

- Pamela Dembski Hart, BS, MT(ASCP), CHSP, Principal and Founder, Healthcare Accreditation Resources, LLC
  - Compliance with Safe Injection Practices: A view from the trenches

- Zack Moore, MD, MPH, Medical Epidemiologist, Communicable Disease Branch, North Carolina Division of Public Health
  - The Doctor and The Mask: Septic arthritis due to unsafe injections in an outpatient clinic

CDC Disclaimer: The findings and conclusions in this presentation are those of the presenter(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Evelyn V. McKnight, AuD. President, HONOReform

Hepatitis C: A Patient’s Perspective, Its’ Causes, and Possible Preventions

CDC Disclaimer: The findings and conclusions in this presentation are those of the presenter(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Joseph Perz, DrPH, MA, CDC's Division of Healthcare Quality Promotion, Team Lead for Quality Standards and Safety in the Prevention and Response Branch
Compliance with Safe Injection Practices
A view from the trenches
The Initial Greeting

What I hear…

…”I think we are pretty good with the regs…”
and......What I Heard

...and then See
Scenario I
What I See and Hear

ASC Procedure Room or OR Set Up

• Medications are prepared in the same area where they are administered

• The CMS Requirement and CDC recommendations
  
  If MDV are used for >1 or multiple patients
  Preparation is in a dedicated / separate area

The response: “We will put the partition up or use a different room when the surveyors (accrediting body) come to inspect”
What I See
And See
Storage Matters
Read the Labels

The pH is adjusted between 6.8 and 7.7 with hydrochloric acid or sodium hydroxide. No preservative added. Each bottle for one procedure only. Discard unused portion. Protect from light. For
Scenario 2
What I see

• Multi-dose vials are not labeled with beyond use dates (BUD) and/or are expired
Scenario 2 cont’d
What I also see

• Dates are incomplete or incorrectly recorded

• Single Dose Vials are not discarded after initial use
# The Solution
## Medication Cart Checklist

<table>
<thead>
<tr>
<th>MONTH</th>
<th>MULTI-DOSE VIALS</th>
<th>SINGLE DOSE VIALS</th>
<th>SYRINGES LABELED</th>
<th>CORRECTIVE PLAN OF ACTION and/or COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Or RM#</td>
<td>Open /In Use</td>
<td>Not Open</td>
<td>Discarded After Each Use</td>
<td>Med Name (MN)</td>
</tr>
<tr>
<td></td>
<td>28 D OK</td>
<td>Initiated</td>
<td>In Date</td>
<td>MN</td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Scenario 2

What I see..... and hear and see

*Observed:*
- QI Study abandoned
  - Anesthesia Medication Cart Daily Checklist

  "no need since everything seemed to be ok"
Scenario 2
What I see...... and see

Observed:
• Anesthesia Medication Cart Daily Checklist

“no need since everything seemed to be ok”

Zofran
After dilution: do not use beyond 24 hours
Contains no preservatives
Scenario 3
What I See

Observed: Inconsistent volume of syringe (narcotic) contents

- IV conscious sedation: Several type narcotics/pre-drawn
- IV (saline) pre-spiked
- IV bags stored on the floor
- MDV pre-spiked

Response:

*The leftover contents of either the syringes or saline solutions are reused for next patient.*

Defense: “IV line or syringe has a safety mechanism in place.”
Pre Spiked IV Bag
Unlabeled Syringe
Scenario 3 and 4
What I hear

“I did not know BOTOX was single use only”

“I did not know SDV could not be used multiple times on the same patient or other patients”

“It is an FDA plot”

“I have used SDV on multiple patients and nothing has happened”

FACT  Single Use, discard 24 hour after reconstitution
The Solution(s)

- Training: Initial and annually
- Random and unannounced Surveys
- Competency exams for license renewal for *all licensees* and in some cases for *non licensees*
Don’t Turn Your Back on Safety

• Primum non nocere
The Doctor and The Mask: Part II
Acknowledgement

- Slides adapted from Dr. Sarah Rhea, DVM, MPH, PhD, presented at 63rd Annual EIS Conference, April 30, 2014
The doctor and the mask: iatrogenic septic arthritis caused by *Streptococcus mitis*

A 72-year-old man developed septic arthritis in a prosthetic shoulder after intra-articular injection of radiographic contrast. This is the first published case in which molecular techniques matched oral commensal organisms cultured from joint aspirate with oral flora from the proceduralist, who was not wearing a mask.

**Clinical record**

A 72-year-old man presented in 2011 with acute-on-chronic right shoulder pain. Bilateral shoulder replacements had been performed 8 years earlier for osteoarthritis, with no surgical complications.

In the 6 months before presentation, the patient experienced increasing pain and decreased range of movement of the right shoulder. Four days before presentation, a computed tomography (CT) arthrogram of the right shoulder was performed to look for glenoid osteolysis and assess the linear integrity of the shoulder prosthesis. Eight millilitres of radiographic contrast with bupivacaine were injected into the joint space. The proceduralist used an aseptic technique and skin preparation with 0.5% alcoholic chlorhexidine, but did not wear a mask. Within 24 hours, the shoulder pain dramatically worsened and the range of movement became severely limited.

**Discussion**

This is the first published instance of a molecular epidemiology technique showing probable transmission of oral flora from a proceduralist to the joint of a patient, resulting in...
October 18, 2013

2 patients hospitalized with *Staphylococcus aureus* (SA) septic arthritis

- Intra-articular injections on same day, by same provider, at same outpatient facility (Facility A)
- Injections contained
  - Autologous platelet-rich plasma (PRP)
  - Allogeneic human placental tissue product
Investigational / alternative therapy for osteoarthritis

Patient’s own blood centrifuged to separate blood components

Plasma injected in joint space (+/- additives)
Investigation Objectives

- Identify additional cases
- Assess for ongoing risk due to
  - Infection control (IC) breach, or
  - Intrinsic contamination of injected product
Methods

- Conducted case finding
  - Contacting other injection recipients
  - National call for cases (Epi-X)
  - FDA MedWatch report
- Assessed IC procedures at Facility A
- Performed cultures of nasal and throat swabs from personnel involved with procedure
Index Cases

- Patient 1
  - Woman >80 years of age
  - Right knee osteoarthritis

- Patient 2
  - Man 49 years of age
  - Cerebral palsy
  - Left knee osteoarthritis
Clinical Presentations

- Intra-articular injection at Facility A on same day in October, 2013
- Joint pain and swelling 24–72 hours after injection
- Hospitalized for surgical debridement
- SA isolates from synovial fluid had same antibiotic-susceptibility profile
Case Finding

- 7 other patients received similar intra-articular injections
  - Procedures ranged from August, 2013–October, 2013
  - No additional cases identified
- No reports identified through hospital records, Epi-X, MedWatch
Visit to Facility A

- Single physician clinic
- Open since July 2013
- Not in compliance with North Carolina requirements for IC
  - No written IC policy
  - No designated staff member to direct IC activities

Procedure room: Site of injection preparation
Review of Injection Procedures

- Procedures temporarily suspended
- Step-by-step walk through

Procedure room: Site of injections
Procedure Description

- Venipuncture
- Blood centrifuged
- Combined autologous PRP
  - Human placental tissue product
  - Other sterile injectable materials (CaCl, thrombin)
- Injection site prepared
- Materials injected into intra-articular space over series of several steps
Infection Control Observations

- Extensive manipulation of sterile medications in ambient air / non-sterile environment
- Intra-articular space accessed multiple times via previously placed needle
- Face masks used inconsistently
Bacterial Culture Results

- 4 personnel present during procedures
  - Physician
  - 2 nurses
  - Company representative
- 3 out of 4 had SA throat carriage
Pulsed-field Gel Electrophoresis (PFGE) Results
Pulsed-field Gel Electrophoresis (PFGE) Results
Conclusions

- Cluster of SA septic arthritis resulted from deficiencies in aseptic technique during joint injection procedures
- Allowed for transmission of oral flora from physician to patients
Limitations

- Direct observation of injection procedure not possible
- Unable to determine whether transmission occurred during preparation or administration
- Unable to discern respiratory droplet versus contact transmission
Aseptic Technique

- Method used to prevent contamination with microorganisms
- During medication preparation, includes
  - Using new sterile syringe and sterile needle to draw up medications
  - Preventing contact between injection materials and non-sterile environment
  - Performing proper hand hygiene
  - Using designated clean medication area
Mask Use?

- Routine use of face masks recommended by HICPAC/CDC for
  - Administering epidural/intrathecal injections
  - Placing central venous catheters

- Routine use of face masks for administering injections in an intracapsular space (joints)
  - Not currently recommended by HICPAC/CDC
  - Recommended by APIC in 2016 position paper

APIC POSITION PAPER: SAFE INJECTION, INFUSION, AND MEDICATION VIAL PRACTICES IN HEALTH CARE (2016)

ASEPTIC TECHNIQUE

- Aseptic technique refers to the use of various barriers and precautions to prevent the transfer of microorganisms from HCP and the environment to the patient during a procedure.³² Sterile is the absence of all microbes.
- Perform hand hygiene (clean hands with alcohol based hand sanitizer or with soap and water) before accessing supplies, handling vials and IV solutions, preparing or administering medications, and conducting point-of-care testing (e.g., blood glucose, coagulation studies, etc.).
- Use aseptic technique in all aspects of parenteral medication preparation, administration, medication vial use, injection, and point-of-care testing.
- Use a mask to contain respiratory droplets when preparing and injecting solution into an intracapsular space (joint), the spine and during lumbar puncture.³³
Discussion

- Careful attention to aseptic technique is needed during
  - Injection procedures
  - Compounding / extensive manipulations of injectable products

- Preparation of injection materials offered opportunity for SA transmission

- Need for increased compliance with state regulations for IC in health care settings
An historic ‘Never Event’:

Don’t let it happen in your facility!

Evelyn V McKnight, AuD
Thomas A McKnight, MD
www.HONOREform.org
Our story
But why?
Major categories of harm in the outbreak

- Silo Culture
- Unsafe Technique
- Few Policy Incentives for Safety
3 Legged stool of patient safety

- Culture
- Design
- Incentives
**Silo culture ➔ Safety culture**

- "team behaviors improves safety culture...provides ability to adapt and learn"*

- AHRQ’s TeamSTEPPS - Strategies & Tools to Enhance Performance and Patient Safety
  “I am Concerned, I am Uncomfortable, This is a Safety Issue”

Unsafe technique ➔ Safety by design

• mitigate unsafe technique
• in US are designed for provider, not patient safety
• in developing markets designed for patient safety

Safety syringes
Few incentives  ➔  Safety incentives

- **Sticks** - only regulatory oversight is provider licensure for private offices: ASC’s have CMS certification
- **Carrots** - Pay for Performance programs such as Physician Quality Reporting System (PQRS)
Our thanks
Before we End Today’s Webinar…

- **Question and Answer Session**
- **Continuing Education**
  - To receive continuing education (CE) you must complete and pass the post-test activity at 80% and complete the webinar evaluation.
  - A link to the post-test and evaluation will appear on your screen as soon as today’s webinar concludes. Please do not exit out.
  - If you exit out of the webinar prior to taking the post-test and evaluation, you can access them from a link we will send to you via an email following today’s webinar.

THANK YOU